ストックスクリーナーアプリを入手
91.41
3.61%
-3.42
アフターアワーズ：
91.41
前日終値:
$94.83
開ける：
$94.54
24時間の取引高:
677.48K
Relative Volume:
0.86
時価総額：
$5.83B
収益：
$46.02M
当期純損益:
$-130.15M
株価収益率:
-44.75
EPS:
-2.0427
ネットキャッシュフロー:
$56.08M
1週間 パフォーマンス:
+3.42%
1か月 パフォーマンス:
+13.31%
6か月 パフォーマンス:
+51.02%
1年 パフォーマンス:
+137.74%
1日の値動き範囲:
$90.35
$94.54
1週間の範囲:
$87.31
$95.43
52週間の値動き範囲:
$37.92
$96.54
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
名前
Protagonist Therapeutics Inc
セクター
電話
(510) 474-0170
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
91.41 | 6.05B | 46.02M | -130.15M | 56.08M | -2.0427 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-12 | 開始されました | Leerink Partners | Outperform |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-12-06 | 開始されました | Goldman | Neutral |
| 2024-11-05 | 開始されました | Wedbush | Outperform |
| 2024-09-24 | 開始されました | TD Cowen | Buy |
| 2024-09-09 | 開始されました | Truist | Buy |
| 2023-10-30 | 開始されました | CapitalOne | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Buy |
| 2021-10-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-11 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-24 | 開始されました | Northland Capital | Outperform |
| 2021-01-06 | 開始されました | JP Morgan | Overweight |
| 2020-12-16 | 開始されました | Piper Sandler | Overweight |
| 2020-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | 開始されました | Jefferies | Buy |
| 2020-05-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-05-09 | アップグレード | Stifel | Hold → Buy |
| 2018-12-06 | 開始されました | Nomura | Buy |
| 2018-01-29 | 開始されました | Stifel | Buy |
| 2017-07-21 | 開始されました | BTIG Research | Buy |
すべてを表示
Protagonist Therapeutics Inc (PTGX) 最新ニュース
Assessing Protagonist Therapeutics (PTGX) Valuation After Strong Recent Share Price Momentum - simplywall.st
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - AOL.com
Is Protagonist Therapeutics (PTGX) Still Attractive After A 136% One Year Share Price Surge - simplywall.st
JPMorgan Chase & Co. Lowers Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) Target Price Raised by Goldman S - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $95.00 - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Strong Buy Ratings and a Promising 14.42% Upside Potential - DirectorsTalk Interviews
TD Asset Management Inc Acquires 34,096 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Wedbush Raises Price Target on Protagonist Therapeutics to $100 From $86, Keeps Outperform Rating - marketscreener.com
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera - lelezard.com
Takeda Pharmaceutical and Protagonist Therapeutics Inc (NASDAQ: PTGX) jointly announced that the U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for their co-developed drug Rusfertide and granted it prior - Bitget
HC Wainwright Has Optimistic Outlook of PTGX Q1 Earnings - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Vanguard Group Inc. - MarketBeat
Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA Filing And Takeda Deal ShiftWhat's Changed - simplywall.st
Citigroup Inc. Has $10.14 Million Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift - Yahoo Finance
Protagonist Therapeutics (PTGX) Quarterly Loss Deepens To US$44.4m And Tests Bullish Profitability Narrative - Sahm
PTGX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance - AOL.com
A Glimpse Into The Expert Outlook On Protagonist Therapeutics Through 8 Analysts - Sahm
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines - TipRanks
Understanding the Setup: (PTGX) and Scalable Risk - Stock Traders Daily
Protagonist Therapeutics (PTGX) Gets Price Target Lift from TD C - GuruFocus
TD Cowen Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $100.00 - MarketBeat
PTGX: Today's Analyst Ratings and Price Target Updates | PTGX St - GuruFocus
Protagonist Therapeutics (PTGX) Sees Analyst Rating Update from Barclays | PTGX Stock News - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $113.00 at Barclays - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $112.00 - MarketBeat
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit - AOL.com
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Desert Sun
Citizens raises Protagonist Therapeutics stock price target on drug approvals - Investing.com UK
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Register-Guard
Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat
Protagonist Therapeutics: Fourth Quarter Earnings Overview - Bitget
Protagonist Therapeutics: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - FinanzNachrichten.de
Protagonist Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Protagonist Therapeutics Q4 revenue drops on lower milestone payments - TradingView
Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q4 Revenue $7.4M - marketscreener.com
[8-K] Protagonist Therapeutics, Inc Reports Material Event | PTGX SEC FilingForm 8-K - Stock Titan
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit - The Motley Fool
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: A Promising Biotech with 17.7% Upside Potential - DirectorsTalk Interviews
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026 - ACCESS Newswire
HC Wainwright raises Protagonist Therapeutics, Inc. (PTGX) target to $117, reiterates buy - MSN
RTW INVESTMENTS, LP Reduces Stake in Protagonist Therapeutics Inc - GuruFocus
Protagonist Therapeutics Inc (PTGX) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):